hepatitis C

J&J moves away from hep C due to rival drugmakers' cures
J&J moves away from hep C due to rival drugmakers' cures
BioPharma Dive
JNJ
hepatitis C
JNJ-4178
R&D
hepatitis B
Flag link:
J&J scraps a multibillion-dollar hepatitis C program after rivals divvy up the market
J&J scraps a multibillion-dollar hepatitis C program after rivals divvy up the market
Endpoints
JNJ
Achillion
hepatitis C
odalasvir
ACH-3102
Flag link:
5 Things Gilead Sciences' Management Just Said That You'll Want to Know
5 Things Gilead Sciences' Management Just Said That You'll Want to Know
Motley Fool
Gilead Sciences
Kite Pharma
HIV
hepatitis C
M&A
Flag link:
Infographic | The leaders of the global hepatitis-C market
Infographic | The leaders of the global hepatitis-C market
Medical Marketing and Media
hepatitis C
Gilead Sciences
Merck
AbbVie
Bristol-Myers Squibb
Flag link:
Medivir out-licenses hep C drug to China’s Ascletis; Cellectis launches pioneering UCART123 US study
Medivir out-licenses hep C drug to China’s Ascletis; Cellectis launches pioneering UCART123 US study
Endpoints
Medvir
hepatitis C
China
Ascletis
Cellectis
UCART123
CAR-T
Flag link:
AbbVie’s new, cheaper hepatitis C drug could launch the drug world’s own Hunger Games
AbbVie’s new, cheaper hepatitis C drug could launch the drug world’s own Hunger Games
Marketwatch
AbbVie
hepatitis C
Mavyret
Gilead Sciences
Merck
Flag link:
Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?
Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?
Motley Fool
AbbVie
Gilead Sciences
hepatitis C
Mavyret
Flag link:
AbbVie's new pan-genotypic hepatitis C drug Mavyret deeply underprices the competition
AbbVie's new pan-genotypic hepatitis C drug Mavyret deeply underprices the competition
Fierce Pharma
AbbVie
hepatitis C
Mavyret
drug pricing
Flag link:
5 Things Gilead Sciences' Q2 Earnings Numbers Didn't Tell You
5 Things Gilead Sciences' Q2 Earnings Numbers Didn't Tell You
Motley Fool
Gilead Sciences
earnings
hepatitis C
HIV
M&A
Flag link:
Gilead Sciences Has 3 Available Options, but Only 1 Makes Sense
Gilead Sciences Has 3 Available Options, but Only 1 Makes Sense
Motley Fool
Gilead Sciences
AbbVie
hepatitis C
reorganization
Flag link:
Gilead Has Another Ace Up Its Sleeve
Gilead Has Another Ace Up Its Sleeve
Seeking Alpha
Gilead Sciences
hepatitis C
Vosevi
Flag link:
How AbbVie Could Hammer Gilead's Hepatitis C Franchise
How AbbVie Could Hammer Gilead's Hepatitis C Franchise
Investors Business Daily
AbbVie
Gilead Sciences
hepatitis C
Vosevi
Harvoni
Sovaldi
Epclusa
Viekira Pak
Flag link:
When It Comes To Abusive Drug Pricing, Don't Confuse Shkreli With Hep C Drugs
When It Comes To Abusive Drug Pricing, Don't Confuse Shkreli With Hep C Drugs
Forbes
drug pricing
hepatitis C
Martin Shkreli
Gilead Sciences
Harvoni
Sovaldi
Flag link:
FDA OKs a new triple hep C drug from Gilead, keeping its grip on a shrinking market
FDA OKs a new triple hep C drug from Gilead, keeping its grip on a shrinking market
Endpoints
Gilead Sciences
FDA
hepatitis C
Vosevi
Flag link:
EMA Recommends New HCV, Cancer and MS Drugs for Approval
EMA Recommends New HCV, Cancer and MS Drugs for Approval
RAPS.org
Europe
EMA
hepatitis C
multiple sclerosis
breast cancer
renal cell carcinoma
AbbVie
Maviret
Gilead Sciences
Vosevi
Biogen
Amgen
Samsung Bioepis
biosimilars
Humira
Novartis
Kisqali
EUSA
Fotivda
Flag link:
Regulus reports a trio of pipeline setbacks
Regulus reports a trio of pipeline setbacks
BioPharma Dive
Regulus
RG-101
RGLS5040
RG-105
cholestatic disease
type 2 diabetes
hepatitis C
Flag link:
U.S. prosecutors zero in on J&J marketing, targeting top immunology, hep C meds
U.S. prosecutors zero in on J&J marketing, targeting top immunology, hep C meds
Fierce Pharma
JNJ
drug manufacturing
immunology
hepatitis C
Remicade
Simponi
Stelara
Olysio
Flag link:
3 Things to Watch With Gilead Sciences, Inc. Q1 Results
3 Things to Watch With Gilead Sciences, Inc. Q1 Results
Motley Fool
Gilead Sciences
earnings
hepatitis C
Genvoya
R&D
Flag link:
Bristol-Myers wins approval in China for oral treatment for chronic hepatitis C virus
Bristol-Myers wins approval in China for oral treatment for chronic hepatitis C virus
Marketwatch
Bristol-Myers Squibb
China
hepatitis C
Daklinza
Flag link:
AbbVie, Enanta post stellar hep C PhIII data, but no one is cheering
AbbVie, Enanta post stellar hep C PhIII data, but no one is cheering
Endpoints
AbbVie
Enanta
hepatitis C
glecaprevir/pibrentasvir
Flag link: